Fresenius SE & Co KGaA (FRE) Given a €52.00 Price Target at Goldman Sachs Group

Share on StockTwits

Goldman Sachs Group set a €52.00 ($60.47) price target on Fresenius SE & Co KGaA (FRA:FRE) in a report published on Friday. The firm currently has a buy rating on the stock.

A number of other research analysts also recently commented on FRE. Credit Suisse Group set a €58.00 ($67.44) price objective on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a research report on Friday, December 7th. Jefferies Financial Group set a €53.00 ($61.63) price objective on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a research report on Thursday, March 7th. Berenberg Bank set a €70.95 ($82.50) price objective on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a research report on Monday, February 18th. UBS Group set a €46.00 ($53.49) target price on shares of Fresenius SE & Co KGaA and gave the stock a neutral rating in a research report on Monday, February 11th. Finally, HSBC set a €55.00 ($63.95) target price on shares of Fresenius SE & Co KGaA and gave the stock a neutral rating in a research report on Wednesday, February 13th. Ten equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock has an average rating of Buy and an average target price of €60.71 ($70.59).

Shares of FRE stock traded down €2.04 ($2.37) during midday trading on Friday, reaching €46.24 ($53.77). 2,460,563 shares of the company were exchanged. Fresenius SE & Co KGaA has a 12 month low of €60.16 ($69.95) and a 12 month high of €80.00 ($93.02).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Featured Story: Hedge Funds – Risk or Reward?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.